13 hours ago
2
Aurobindo Pharma subsidiary Eugia Pharma Specialities’ formulation manufacturing installation adjacent Hyderabad has been classified by the U.S. Food and Drug Administration (U.S. FDA) arsenic “official enactment indicated” (OAI).
One of the 3 classifications that the regulator assigns to facilities post-inspection is OAI, which means it is recommending regulatory and/or administrative actions.
Aurobindo Pharma is expecting nary interaction connected the company’s financials oregon operations owed to the action. The institution is committed to maintaining the highest prime manufacturing standards astatine each of its facilities crossed the globe, it said connected Friday (June 12, 2026) successful a filing connected the U.S. FDA classification.
The U.S. FDA had inspected the Unit-III formulation manufacturing installation of Eugia Pharma Specialities successful IDA, Pashamylaram, Hyderabad, from January 27 to February 6. The inspection had concluded with 11 observations.
“The FDA has present determined that the inspection classification of this installation is authoritative enactment indicated (OAI),” Aurobindo Pharma said successful the filing.
Also read: U.S. FDA classifies Aurobindo arm’s formulation portion Official Action Indicated
Besides OAI, the different 2 classifications the U.S. FDA issues are No Action Indicated (NAI), which conveys that nary objectionable conditions oregon practices were recovered post-inspection, and Voluntary Action Indicated (VAI), which means that objectionable conditions oregon practices were found, but the regulator is not prepared to instrumentality oregon urge immoderate administrative oregon regulatory action.
This is the 2nd works of the Aurobindo subsidiary to beryllium classified arsenic OAI. The U.S. FDA had besides determined Eugia Pharma Specialities’ formulation manufacturing installation successful Kolthur colony of Ranga Reddy district, adjacent Hyderabad, to beryllium OAI successful May.
